Why Most Longevity Research Fails and 4 Drug Classes That Actually Work

The longevity field faces a critical reproducibility crisis that has destroyed hundreds of millions in investment capital while damaging scientific credibility. Dr. Stanfield illustrates this through two major failures: resveratrol research that cost GSK $720 million with no reproducible results, and ovarian stem cell research that led to investor lawsuits and SEC fraud charges before complete company collapse.

The core problem follows a predictable pattern: exciting initial lab discoveries trigger massive investment flows, only to reveal years later that results cannot be replicated. This mirrors broader scientific issues, exemplified by cancer research where only 6 of 53 foundational studies proved reproducible when tested by Amgen, explaining disappointing clinical translation rates.

Stanfield proposes using the Interventions Testing Program as a validation model, which tests compounds simultaneously across three labs using genetically diverse mice. This approach has already saved capital by revealing that popular supplements like fisetin and nicotinamide riboside show no lifespan benefits, despite widespread marketing claims.

Four medication classes show genuine promise based on robust evidence: SGLT2 inhibitors extend male mouse lifespan 14% and benefit heart/kidney health in humans; rapamycin consistently extends mouse lifespan 17-25% with emerging human safety data; GLP-1 medications offer metabolic benefits beyond diabetes; and PCSK9 inhibitors could revolutionize cardiovascular disease prevention with six-month dosing intervals.

Additionally, non-ablative skin devices represent validated approaches for aging reversal without significant recovery time. The fundamental lesson emphasizes validating interventions thoroughly before scaling, building on reproducible science rather than chasing hype-driven opportunities that ultimately waste precious resources and damage field credibility.